Plasma AGE and Oxidation Products, Renal Function, and Preeclampsia in Pregnant Women with Type 1 Diabetes: A Prospective Observational Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Hindawi Limited Country of Publication: England NLM ID: 101605237 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6753 (Electronic) NLM ISO Abbreviation: J Diabetes Res Subsets: MEDLINE
    • Publication Information:
      Publication: <2019>-: London, United Kingdom : Hindawi Limited
      Original Publication: Nasr City, Cairo : Hindawi Publishing Corporation, [2013]-
    • Subject Terms:
      Diabetes Mellitus, Type 1* ; Pre-Eclampsia*; Pregnancy ; Humans ; Female ; Pregnant Women ; Reference Values ; Glycation End Products, Advanced ; Kidney/physiology
    • Abstract:
      Aims: We aimed to determine whether plasma advanced glycation end products or oxidation products (AGE/oxidation-P) predict altered renal function and/or preeclampsia (PE) in pregnant women with type 1 diabetes.
      Methods: Prospectively, using a nested case-control design, we studied 47 pregnant women with type 1 diabetes, of whom 23 developed PE and 24 did not. Nineteen nondiabetic, normotensive pregnant women provided reference values. In plasma obtained at ~12, 22, and 32 weeks' gestation (visits 1, 2, and 3; V1-V3), we measured five AGE products (carboxymethyllysine (CML), carboxyethyl-lysine (CEL), methylglyoxal-hydroimidazolone (MGH1), 3-deoxyglucosone hydroimidazolone (3DGH), and glyoxal-hydroimidazolone (GH1)) and four oxidation products (methionine sulfoxide (MetSO), 2-aminoadipic acid (2-AAA), 3-nitrotyrosine (3NT), and dityrosine (DT)), by liquid chromatography/mass spectroscopy. Clinical outcomes were "estimated glomerular filtration rate" (eGFR) at each visit and onset of PE.
      Results: In diabetic women, associations between AGE/oxidation-P and eGFR were found only in those who developed PE. In this group, CEL, MGH1, and GH1 at V2 and CML, CEL, MGH1, and GH1 at V3 were inversely associated with contemporaneous eGFR, while CEL, MGH1, 3DGH, and GH1 at V2 were inversely associated with eGFR at V3 (all p < 0.05). There were no associations of plasma AGE or oxidation-P with pregnancy-related development of proteinuria or PE.
      Conclusions: Inverse associations of second and early third trimester plasma AGE with eGFR among type 1 diabetic women who developed PE suggest that these patients constitute a subset susceptible to AGE-mediated injury and thus to cardiorenal complications later in life. However, AGE/oxidation-P did not predict PE in type 1 diabetic women.
      Competing Interests: The authors have declared that no conflict of interest exists.
      (Copyright © 2023 Clare B. Kelly et al.)
    • References:
      J Nutr. 2021 May 11;151(5):1128-1138. (PMID: 33693835)
      Free Radic Res. 2013 Aug;47 Suppl 1:70-80. (PMID: 23796030)
      N Engl J Med. 1991 Sep 19;325(12):836-42. (PMID: 1875967)
      Diabetes Care. 2022 Mar 1;45(3):684-691. (PMID: 35051276)
      Diabetes. 2015 Jan;64(1):266-78. (PMID: 25187362)
      J Hypertens. 2013 Jan;31(1):16-26. (PMID: 23188419)
      Circ Res. 2003 Dec 12;93(12):1159-69. (PMID: 14670831)
      Clin Biochem. 2010 Mar;43(4-5):442-6. (PMID: 19909734)
      Placenta. 2006 Feb-Mar;27(2-3):225-33. (PMID: 16338468)
      Placenta. 2013 Dec;34(12):1177-82. (PMID: 24144948)
      FASEB J. 2008 May;22(5):1572-80. (PMID: 18089847)
      N Engl J Med. 2004 Feb 12;350(7):672-83. (PMID: 14764923)
      BMJ Open Diabetes Res Care. 2021 Jan;9(1):. (PMID: 33504507)
      Gynecol Obstet Invest. 2017;82(4):388-397. (PMID: 27505171)
      Arterioscler Thromb Vasc Biol. 2019 May;39(5):925-933. (PMID: 30917679)
      Diabetes Care. 2018 Jan;41(1):120-127. (PMID: 29122892)
      Diabetes Care. 2018 Mar;41(3):570-576. (PMID: 29208654)
      Proc Natl Acad Sci U S A. 1984 Jan;81(2):583-7. (PMID: 6582514)
      Diabetes. 2016 Dec;65(12):3744-3753. (PMID: 27609106)
      J Clin Endocrinol Metab. 2012 May;97(5):1752-62. (PMID: 22438226)
      Diabetologia. 2017 Dec;60(12):2514-2524. (PMID: 28875223)
      Am J Reprod Immunol. 2016 Feb;75(2):172-80. (PMID: 26682535)
      BMJ. 2017 Jul 12;358:j3078. (PMID: 28701333)
      Eur J Pharmacol. 2018 Aug 15;833:158-164. (PMID: 29883668)
      Coron Artery Dis. 2009 Jun;20(4):267-73. (PMID: 19440065)
      J Biol Chem. 1992 Jul 25;267(21):14998-5004. (PMID: 1378843)
      Amino Acids. 2014 Feb;46(2):311-9. (PMID: 24036985)
      PLoS Med. 2019 Jul 30;16(7):e1002875. (PMID: 31361741)
      Diabetologia. 2006 Oct;49(10):2488-98. (PMID: 16955213)
      Diabetes Care. 2011 Jun;34(6):1258-64. (PMID: 21498785)
      J Nutr. 2010 Sep;140(9):1582-7. (PMID: 20660279)
      AJOG Glob Rep. 2022 Feb 26;2(2):100052. (PMID: 36275494)
      Am J Perinatol. 1993 Jul;10(4):330-3. (PMID: 8397576)
      Eur J Epidemiol. 2013 Jan;28(1):1-19. (PMID: 23397514)
      J Clin Invest. 1993 Jun;91(6):2463-9. (PMID: 8514858)
      Nat Rev Drug Discov. 2021 Oct;20(10):770-788. (PMID: 34262140)
      Diabetes Rev (Alex). 1997;5(4):365-391. (PMID: 26366051)
      FASEB J. 2008 Oct;22(10):3716-27. (PMID: 18603587)
      Kidney Int. 1998 Feb;53(2):416-22. (PMID: 9461101)
      BJOG. 2012 Nov;119(12):1512-20. (PMID: 22900949)
      Diabetes Care. 2017 Apr;40(4):591-598. (PMID: 28148544)
      Am J Physiol Endocrinol Metab. 2001 May;280(5):E685-94. (PMID: 11287350)
      Diabetologia. 2009 Jan;52(1):160-8. (PMID: 18985316)
      Diabetes Care. 2013 Jul;36(7):2054-61. (PMID: 23393212)
    • Accession Number:
      0 (Glycation End Products, Advanced)
    • Publication Date:
      Date Created: 20230821 Date Completed: 20230822 Latest Revision: 20230823
    • Publication Date:
      20231215
    • Accession Number:
      PMC10435306
    • Accession Number:
      10.1155/2023/8537693
    • Accession Number:
      37601831